Eli Lilly and Company (NYSE:LLY) Stock Falls 1.1% – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s stock price dropped 1.1% during trading on Monday. The company traded as low as $1,239.10 and last traded at $1,242.7580. 1,947,631 shares traded hands during trading, a decline of 34% from the average daily volume of 2,949,663 shares. The stock had previously closed at $1,257.03.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo could gain market share: Bank of America expects Lilly’s oral GLP-1 treatment, Foundayo, to continue gaining share over the next 12 months. Separately, European regulators recommended approval, potentially expanding Lilly’s obesity-drug reach and supporting sales growth. Foundayo market-share article European Foundayo approval article
• Positive Sentiment: Positive Omvoh pediatric data: Omvoh met the primary endpoint in a Phase 3 pediatric ulcerative-colitis study. Among induction responders, 50% achieved clinical remission at one year, with Lilly planning regulatory submissions for a potential label expansion. Omvoh pediatric trial article
• Positive Sentiment: Pipeline and technology investments: Lilly will present new oncology data at the ESMO Congress and agreed to pay Metis TechBio up to $1.1 billion for AI-enabled drug-delivery technology. These developments could broaden Lilly’s future product base beyond obesity medicines. Metis TechBio deal article
• Neutral Sentiment: Analyst and investor debate: RBC reiterated a Buy view, while multiple analyses questioned whether Lilly’s rapid growth, improving margins and upcoming medicines—including retatrutide—can support its elevated valuation.
• Negative Sentiment: Competition and concentration risks: Investors are monitoring a potential price war with Novo Nordisk and Lilly’s heavy dependence on its obesity portfolio, which could pressure pricing or magnify the impact of disappointing product results.
• Negative Sentiment: Insulin-price lawsuit: A Pennsylvania complaint alleges Lilly and other manufacturers inflated insulin prices by more than 1,000%. The allegations could create legal costs, reputational damage and additional pricing scrutiny, although no liability has been established. Lilly insulin lawsuit article

Analysts Set New Price Targets

LLY has been the subject of a number of recent research reports. Citigroup boosted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $1,500.00 target price on shares of Eli Lilly and Company in a report on Monday, October 12th. Leerink Partners lifted their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, TD Cowen reiterated a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Stock Down 1.1%

The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market cap of $1.17 trillion, a P/E ratio of 41.70, a PEG ratio of 1.67 and a beta of 0.46. The stock has a 50-day moving average of $1,180.08 and a 200 day moving average of $1,109.55.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts anticipate that Eli Lilly and Company will post 33.56 earnings per share for the current year.

Insider Activity

In other news, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Coastal Bridge Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $2,959,000. Mosaic Family Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after purchasing an additional 1,430 shares during the last quarter. Moran Wealth Management LLC increased its position in Eli Lilly and Company by 85.6% during the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after purchasing an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC increased its position in Eli Lilly and Company by 17.5% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after purchasing an additional 1,521 shares in the last quarter. Finally, Amundi lifted its stake in Eli Lilly and Company by 9.9% in the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after purchasing an additional 454,549 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.